Dr. Boguski will provide thought leadership as well as strategic direction to enable healthcare organizations to implement precision medicine programs, share information and optimize operations to improve clinical outcomes.
Tampa, FL (PRWEB) April 18, 2017
Cancer diagnostics and pathology workflow solution provider Inspirata®, Inc. announced today that Dr. Mark Boguski has been appointed to the role of Chief Medical Officer (CMO) – Precision Medicine, overseeing strategic planning and implementation of Inspirata’s precision medicine solutions.
“Dr. Boguski is widely considered a visionary leader in precision medicine, and he has extensive experience in oncology, biomedical informatics, genomics, molecular profiling,” says Inspirata CEO Satish Sanan. “In his new role as CMO, Dr. Boguski will provide thought leadership as well as strategic direction to enable healthcare organizations to implement precision medicine programs, share information and optimize operations to improve clinical outcomes.”
Prior to joining Inspirata in September 2016, Dr. Boguski was the CMO and Co-founder of Precision Medicine Network, Inc., (PMNI), where he created a molecular oncology knowledge visualization and decision support platform, called “Crosswalk Insight™: Oncology.” A pathologist by training, Dr. Boguski envisioned Crosswalk empowering the oncology care team with the necessary molecular proficiency to support the widespread adoption of precision medicine.
Since its acquisition of PMNI, Inspirata has integrated the Crosswalk platform into its existing cancer diagnostic workflow solution and its pathology consultation portal. Crosswalk is used by healthcare professionals as well as patients to easily understand and communicate critical cancer information, associated molecular pathways, targeted therapies and clinical trials. Crosswalk is easily integrated within the existing healthcare IT environment and is also available on iOS and Android mobile devices and desktop systems.
During his distinguished career, Dr. Boguski has held faculty positions at Harvard Medical School, Johns Hopkins University School of Medicine, the National Institutes of Health and National Library of Medicine, and he has had executive positions in the biotechnology and pharmaceutical industries. He founded the Genomic Medicine Initiative at Beth Israel Deaconess Medical Center in Boston, and is an elected member of the U.S. National Academy of Medicine.
About Inspirata, Inc.
Inspirata®, Inc. offers the most comprehensive cancer diagnostics workflow solution available for precision diagnosis today. The solution, which employs a unique “solution-as-a-service” business and delivery model, accelerates anatomic and molecular pathology workflows and facilitates whole slide imaging and image analytics, prognostic and predictive assays, remote consultations and tumor boards. This comprehensive solution includes an Enterprise Service Bus (ESB) to help to solve interoperability issues and a Natural Language Processing Engine (NLP) for structuring data. Inspirata amalgamates this structured data into a central multi-institutional and multi-modal big data cancer repository for clinical, research and educational purposes. Its use will extend to physicians, patients, researchers and pharma among others. This comprehensive solution facilitates a modern precision diagnosis to build a strong foundation for precision medicine. For more information, please visit http://www.inspirata.com or contact firstname.lastname@example.org.